FDA PMTA, MGO, and MRTP: What These Terms Actually Mean
News coverage often collapses “FDA authorized” and “FDA said it’s safer” into the same idea. They’re not the same regulatory decision, and the difference matters if you want to know what’s actually been established about a specific product.
PMTA: the application, not the approval
A Premarket Tobacco Product Application (PMTA) is the application a company files with the FDA under the Tobacco Control Act to get permission to sell a new tobacco product — including nicotine pouches, even though they contain no tobacco leaf, because the nicotine in most of them falls under FDA’s authority. Filing a PMTA doesn’t mean anything is approved yet; it just starts the review.
Marketing Granted Order (MGO): permission to sell
If FDA reviews a PMTA and decides that authorizing the product is “appropriate for the protection of public health” — a population-level standard that weighs effects on both current users and non-users — it issues a Marketing Granted Order. This is what lets a specific product (a specific brand, flavor, and strength) be legally sold in the US.
An MGO does not authorize any claim that the product is lower-risk than anything else. It’s simply permission to sell, based on evidence about the product’s composition, toxicology, and likely effects on the population.
Modified Risk Tobacco Product (MRTP) order: permission to make a specific claim
A separate, higher bar applies to comparative risk claims. Under a different section of the law, a company can apply for an MRTP order — and there are two kinds:
- Risk modification order: requires evidence the product, as actually used, significantly reduces harm and disease risk to individual users and benefits the health of the population as a whole, including people who don’t currently use tobacco.
- Exposure modification order: requires evidence of a substantial reduction in exposure to specific harmful substances, that consumers actually get that reduced exposure in real use, and evidence connecting that reduction to a measurable drop in disease and death.
This is the pathway that let Philip Morris International state, for 20 specific ZYN products, that switching from cigarettes lowers the risk of several diseases — but only for people switching completely, under a five-year order subject to revocation if population-level data (like a spike in youth use) undercuts the public-health benefit.
Why the distinction matters when you’re reading about a product
- A brand with an MGO but no MRTP order can legally be sold — but can’t legally claim it’s lower-risk than anything else.
- Most nicotine pouch brands on the US market have neither — they’re sold widely despite not having completed PMTA review, which is a separate enforcement gap, not a legal endorsement.
- Only a specific, narrow slice of ZYN’s lineup currently holds both an MGO and an MRTP order. That authorization doesn’t extend to ZYN’s whole product line, and it doesn’t extend to any other brand.
See our full US legal status page for how this plays out for nicotine pouches specifically, and our explainer on the ZYN order itself for what that specific authorization says.